SMN Modulators Enhancing Splicing Accuracy for SMA Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for Spinal Muscular Atrophy (SMA) are inadequate, with no cure available and limited methods for modulating Survival of Motor Neuron (SMN) protein levels, which are critical for treating SMA and related conditions.
Innovation Solution
Development of SMN modulators, specifically compounds represented by Formula (I) and their salts, which can increase full-length SMN (FL-SMN) and SMNΔ7 levels by activating the SMN promoter, preventing exon 7 splicing, and stabilizing SMN protein, thereby addressing the low levels of functional SMN protein in SMA patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic strategies are used for SMA, then treatment options are limited, but SMN protein levels remain insufficient for effective therapy
Solution Approach 1:
The patent applies parameter changes by modifying splicing factors (SF3b complex components) to alter the splicing pattern of SMN2 pre-mRNA. This changes the biological parameter of exon 7 inclusion, transforming the low-yield alternative splicing into high-yield constitutive splicing, thereby increasing functional SMN protein levels from trace amounts to therapeutic concentrations.
Solution Approach 2:
The patent introduces intermediary molecules or genetic elements that target and modify the splicing machinery. Specifically, it uses components of the SF3b complex as intermediaries to bridge the gap between SMN2 gene and functional SMN protein production, enabling the splicing apparatus to correctly include exon 7 in the mature mRNA.
2Quantity of substance
If SMN2 gene is relied upon for SMN protein production, then full-length SMN can be produced, but only at very low levels due to alternative splicing
Solution Approach 1:
The patent implements feedback mechanisms where the splicing factors are regulated based on cellular SMN protein levels. The SF3b complex components are modulated in response to detected splicing inefficiencies, creating a feedback loop that adjusts splicing factor activity to optimize exon 7 inclusion and maintain appropriate SMN protein production levels.
Solution Approach 2:
The patent applies preliminary action by pre-modifying the splicing machinery before SMN2 pre-mRNA processing occurs. The SF3b complex is prepared and positioned in advance to recognize and bind to specific sequences in the SMN2 pre-mRNA, preventing alternative splicing events before they can occur and ensuring constitutive splicing of exon 7.
Data Source
AI summary
The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.